Details for New Drug Application (NDA): 008372
✉ Email this page to a colleague
The generic ingredient in ACTHAR GEL (AUTOINJECTOR) is corticotropin. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the corticotropin profile page.
Summary for 008372
Tradename: | ACTHAR GEL (AUTOINJECTOR) |
Applicant: | Mallinckrodt Ard |
Ingredient: | corticotropin |
Patents: | 1 |
Suppliers and Packaging for NDA: 008372
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ACTHAR GEL | corticotropin | INJECTABLE;INJECTION | 008372 | NDA | Mallinckrodt ARD LLC | 63004-8710 | 63004-8710-1 | 1 VIAL, MULTI-DOSE in 1 CARTON (63004-8710-1) / 5 mL in 1 VIAL, MULTI-DOSE |
ACTHAR GEL (AUTOINJECTOR) | corticotropin | INJECTABLE;INJECTION | 008372 | NDA | Mallinckrodt ARD LLC | 63004-8710 | 63004-8710-1 | 1 VIAL, MULTI-DOSE in 1 CARTON (63004-8710-1) / 5 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 40 UNITS/0.5ML | ||||
Approval Date: | Feb 29, 2024 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 25, 2041 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 25, 2041 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Feb 25, 2041 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING |
Complete Access Available with Subscription